Introduction: Cervical cancer (CC) remains a significant public health challenge in Brazil, ranking as the fifth most frequent malignant neoplasm among women. Despite established screening strategies such as the Cervical Cancer Prevention Exam, the country continues to report high incidence and mortality rates, particularly in the Northern and Northeastern regions. Since 2014, Brazil has implemented Human Papillomavirus (HPV) vaccination through its Unified Health System (SUS, as per its Portuguese acronym). Persistent socioeconomic inequalities and limitations in ensuring early diagnosis and appropriate treatment contribute to this ongoing burden. Objectives: To analyze the epidemiological profile of cervical cancer in the municipalities of Belém and Ananindeua from 2010 to 2019. Methods: This epidemiological, descriptive, and retrospective study adopts an ecological approach using secondary data. Incidence data encompass new cervical cancer cases recorded between 2010 and 2019 from the Population-Based Cancer Registries of Belém and Ananindeua. Mortality data were extracted from the Mortality Information System (SIM, as per its Portuguese acronym) for the same period. Variables included diagnosis/death year and age group. As the study relied solely on publicly accessible secondary data, ethical review by a Research Ethics Committee was waived. Results: Between 2010 and 2019, mortality rates in Belém and Ananindeua fluctuated significantly. In Ananindeua, crude rates ranged from 5.06% to 12.24% per 100,000 women, while Belém exhibited rates between 8.35% and 13.41%. Age-adjusted rates corresponded to 4.74%–12.71% in Ananindeua and 7.96%–10.65% in Belém, indicating a high disease burden or persistent risk factors in the capital. Mortality increased with age: in Belém, the highest rates affected women aged 70–79 years (51.73%) and ?80 years (48.08%), while in Ananindeua, the peak was among those aged 60–69 years (34.94%). No cases were recorded under 20 years of age. Regarding incidence, the 35–44 age group had the highest number of cases (307 per subgroup), followed by 30–34 years (188 cases), with an annual average of 2,757 cases. Comparative analysis of crude and adjusted rates highlighted demographic influences. A decline post-2017, potentially linked to HPV vaccine expansion, was observed. However, elevated rates among elderly women underscore gaps in screening and healthcare support. Conclusion: This study demonstrates persistently high cervical cancer incidence and mortality rates in Belém and Ananindeua, particularly among elderly women. The comparative analysis suggests that HPV vaccination efforts may have contributed to post-2017 reductions. These findings underscore the urgent need to enhance screening programs and healthcare infrastructure to mitigate disease burden in this population.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
